An interventional study of Soybean oil (Standard treatment) and Eicosapentaenoic acid (omega-3 fatty acid) in Major Depressive Disorder (MDD), sponsored by National Science and Technology Council, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 33rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2025, is one of 26 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 65th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Argentina and 4 more countries
Ages 18–74
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Brazil and 4 more countries
Ages 12–17
Neurocrine Biosciences · Sites in Taiwan, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 19 · Phase 4 10
First in 2005; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 128 across the 64 interventional studies, 160 across the 5 observational. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
National Science and Technology Council, Taiwan is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
National Science and Technology Council, Taiwan has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder, Major with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04637620China Medical University HospitalNMDA Modulation in Major Depressive Disorder | 2026-11 |
| NCT05136755China Medical University HospitalNMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder | 2026-11 |
| NCT06821646National Taiwan University HospitalInvestigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography | 2026-12-31 |
| NCT07500714National Science and Technology Council, TaiwanIntegrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
3 gram/day
Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)
Soy Bean Oil, 3 gram/day
Dietary Supplement: Soybean oil (Standard treatment)
3g/day of Soybean Oil
3 grams/day
Depressive Symptoms
The 17-item version (HAMD-17) is used to quantify the severity of depression. A score of ≥18 shows a significant depression level.
Time frame: Weeks 0, 4, 8, 12, 16, 24
Depressive Symptoms
The GDS-15 (15-item Geriatric Depression Scale), a score of 5 or higher (≥5) indicates the presence of depression, or "clinically relevant" depressive symptoms.
Time frame: Weeks 0, 4, 8, 12, 16, 24
Depressive Symptoms
The 20-item Center for Epidemiological Studies Depression Scale (CES-D) to indicate significant, or "clinical," depressive symptoms is a total score higher than or equal to 16.
Time frame: Weeks 0, 4, 8, 12, 16, 24
Depressive Symptoms
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician-administered scale with a total score range of 0 to 60, where higher scores indicate more severe depression.
Time frame: Weeks 0, 4, 8, 12, 16, 24
Executive Functioning
The Trail Making Test (TMT) evaluates cognitive impairment by measuring the time (in seconds) to complete tasks. Higher scores indicate slower, more impaired performance.
Time frame: Weeks 0, 4, 12, 24
Executive Functioning
Based on clinical literature, the Reliable Digit Span (RDS)-a raw score sum of the longest string of digits recalled forward and backward-is a common embedded measure of executive functioning and performance validity. Below 7 indicates a need for caution regarding the validity of the patient's cognitive effort or indicates a potential decline in working memory/attention.
Time frame: Weeks 0, 4, 12, 24
Executive Functioning
The Modified Wisconsin Card Sorting Test (M-WCST) assesses executive functioning, with higher scores indicating greater dysfunction or impairment.
Time frame: Weeks 0, 4, 12, 24
General Cognitive Ability and Memory & Attention
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) uses age-corrected index scores (Mean=100, SD=15) to identify cognitive impairment. Cutoff points for identifying impairment are set at 1 or 1.5 standard deviations (SD) below the mean.
Time frame: Weeks 0, 4, 12, 24
Processing Speed
Commonly used cut-off points for identifying cognitive impairment using the Digit Symbol Substitution Test (DSST) often fall within the range of lower than or equal to 25-35 points.
Time frame: Weeks 0, 4, 12, 24
Gut microbiome composition
Gut microbiota composition is primarily measured by analyzing microbial DNA extracted from fecal (stool) samples.
Time frame: Weeks 0 and 24
Fatty Acids Profiles in Blood
Fatty acid (FA) profiles in blood (red blood cells) are primarily measured using gas chromatography (GC).
Time frame: Weeks 0 and 24
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 32 months is close to that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eicosapentaenoic Acid
National Science and Technology Council, Taiwan